正在加载公司
Just reported
From Emergent Biosolutions's results release of 2026年11月2日; its quarterly report has since been filed.
Actual
US$110M
-52% y/y
-53% q/q
Guided
US$120M
midpoint
Actual
-US$0.64
Guided
—
No guide given
Actual
-US$37.3M
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The themes Emergent Biosolutions is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
TAKTakeda Pharmaceutical Company LimitedUS$34.4BA
NBIXNeurocrine Biosciences, Inc.US$16.9BA+
ELANElanco Animal Health IncorporatedUS$13.4BA
KNSAKiniksa Pharmaceuticals International, plcUS$8.2BA+
LQDALiquidia CorporationUS$5.2BARose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation2026年10月21日CBGraded C, now B
MCKMckesson Corporation2026年11月4日BAGraded B, now A
CVSCVS Health Corp2026年11月4日BAGraded B, now A
EWEdwards Lifesciences Corporation2026年11月4日BAGraded B, now A
GEHCGE Healthcare Technologies Inc.2026年10月28日CAGraded C, now A基于 Emergent Biosolutions Inc. 自己向美国证券交易委员会（SEC）提交的申报文件。数字如实呈报，每股历史已重述到今天的股数口径。 这是对一门生意的描述——不是投资建议，也不是买卖任何证券的推荐。
公司指引：2026 财年营收 US$600M 至 US$645M — 同比下降 16.2%（上年同期 US$742.9M）
Grade D
价格下方的色带显示每个日期的评级，仅依据当时已公开的文件计算。
显示 Emergent Biosolutions Inc. 评级历史 41 个季度中的 2 个。 其余 39 个可回溯到 2016年11月。
